Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial-Reference-Cited by-同舟云学术

Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial

Published:2007-03 Issue:3 Volume:51 Page:739-748
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Droz Jean-Pierre,Kramar Andrew,Biron Pierre,Pico José-Luis,Kerbrat Pierre,Pény Jean,Curé Hervé,Chevreau Christine,Théodore Christine,Bouzy Jeannine,Culine Stéphane

Publisher

Elsevier BV

Subject

Urology

Reference39 articles.

1. Treatment of testicular cancer: a new and improved model;Einhorn;J Clin Oncol,1990

2. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer;Einhorn;Ann Intern Med,1977

3. Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” platinum combination chemotherapy regimen;Ozols;Cancer,1983

4. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors;Ozols;J Clin Oncol,1988

5. A phase I-II trial of intensive chemotherapy with autologous bone-marrow transplantation in metastatic malignant germ cell tumors of the testis;Droz;Prog Clin Biol Res,1985

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial;Journal of Clinical Oncology;2024-08-21

2. Management;A Guide to Management of Urological Cancers;2023

3. Advances in diagnosis and treatment of testicular cancer;BMJ;2022-11-28

4. Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study;Malignant tumours;2022-07-19

5. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer;Canadian Urological Association Journal;2022-05-31